NEW YORK (GenomeWeb News) – Sangamo BioSciences today announced that it has entered into a licensing agreement with Palo Alto, Calif.-based Open Monoclonal Technologies, under which OMT obtained non-exclusive, worldwide rights to develop transgenic animals using Sangamo’s proprietary zinc finger DNA-binding technology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.